Despite these differences, both conditions share a common underlying mechanism driven by dysregulation of the IL-23/IL-17 axis.[48,49] The systemic inflammation characteristic of PsA, driven by elevated levels of IL-17 and TNF-α, may contribute to the heightened risk of thyroid diseases in psoriasis patients. This evidence concerns the gene IL17A and thyroid gland disorder.